



B · M O R E

B.More to Present at Psychedelic Capital

Greenwich, Connecticut, September 20, 2022 – B.More Inc., a 501(c)(3) non-profit, clinical-stage biopharmaceutical company focused on the development of psychedelic medicines for substance abuse disorders, today announced that its Chief Medical Officer, Judy Ashworth, and it's Lead Site Principal Investigator, Dr. Michael Bogenschutz, Director of the NYU Langone Center for Psychedelic Medicine, will participate virtually during Psych Capital on Thursday, September 29th. Their presentation, which will focus on the results of Dr. Bogenschutz's recently published Phase 2a psilocybin for alcohol use disorder trial and how B.More will move from the trial's positive findings to an FDA approved treatment, will be available beginning at 1:45pm Eastern Time.

For details or to register to attend please visit:

<https://microdose.buzz/shop/events/psychedelic-capital/psychedelic-capital-sept-2022/>

About B.More

Founded in 2017 by Carey and Claudia Turnbull, B.More is a 501(c)(3) non-profit, clinical-stage biopharmaceutical company with a mission to develop better treatment options for those struggling with alcohol use disorder and other substance use disorders. Named after Claudia Turnbull's brother, Brett Moore, who died of a drug overdose 50 years ago, B.More is focused on the development and commercialization of psychedelic medicines that offer the potential to dramatically improve the lives of those for whom current treatment options have not proved effective. Based on a long history of partnership with researchers at the NYU School of Medicine, B.More is advancing clinical research to help these individuals and their loved ones live a better tomorrow.

For more information, please visit www.bmoreinc.org

Media inquiries:

Contact: Christopher Koddermann

Tel.: +41 (79) 434 25 78

E-Mail: chris@nyprg.org